Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05900466 · ClinicalTrials.gov registry record · Phase 2
Metformin for Fibromyalgia Symptoms (INFORM Trial)
A Phase 2 study of Fibromyalgia Syndrome, sponsored by University of Utah.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT05900466 is a Phase 2 study of Fibromyalgia Syndrome that is actively recruiting participants, run by University of Utah. The registered enrollment target is 72 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05900466, a Phase 2 study of Fibromyalgia Syndrome, is actively recruiting participants, sponsored by University of Utah.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of the project is to evaluate the safety and efficacy of low dose metformin for improving symptoms associated with fibromyalgia syndrome (FMS) via modulating neuroinflammatory pathways. The investigators hypothesize that FMS patients in the low-dose metformin conditions will show greater improvement in FMS symptoms than those who are in the placebo group. Further, the investigators hypothesize that metformin will increase phosphorylated AMPK in peripheral immune cells of FMS patients and will decrease the transcription of mTORC1, NLRP3 inflammasome, and nociceptive cytokines interleukin 1beta and interleukin 18.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Metformin
Study Locations (1)
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2023-04-01 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05900466
The ClinicalTrials.gov registry entry for NCT05900466 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fibromyalgia Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05900466 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT05900466 about?
NCT05900466 is a clinical study titled "Metformin for Fibromyalgia Symptoms (INFORM Trial)". The main purpose of the project is to evaluate the safety and efficacy of low dose metformin for improving symptoms associated with fibromyalgia syndrome (FMS) via modulating neuroinflammatory pathways. The investigators hypothesize that FMS patients in the low-dose metformin conditions will show gr...
What is the current status of trial NCT05900466?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2023-04-01. Estimated completion is 2026-03-31.
What conditions does trial NCT05900466 study?
This clinical trial studies the following conditions: Fibromyalgia Syndrome.
What interventions are being tested in trial NCT05900466?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG).
Who is sponsoring clinical trial NCT05900466?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05900466 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fibromyalgia Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.